
|Videos|November 17, 2022
Dr. Morris on how PSMA-PET imaging has “exploded” in the past year
Author(s)Urology Times staff
“As the PSMA-PET market for access has grown, the coverage has actually been better than we anticipated when it first launched,” says David Morris, MD.
Advertisement
David Morris, MD, Urology Associates, Nashville, TN, discusses how PSMA-PET imaging is revolutionizing prostate cancer care. “We all recognize it’s better than conventional imaging in terms of finding metastatic lesions and with that, it enables us to grow our potential patient based for targeted therapies.” says Morris.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Individualizing androgen pathway therapy in mCSPC
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












